Medicare Enrolled
Dr. Andrew Kovoor, MD
Hematology & Oncology · Plano, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kovoor from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kovoor? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kovoor
Dr. Andrew Kovoor is a hematology & oncology in Plano, TX, with 13 years in practice. Based on federal Medicare data, Dr. Kovoor performed 108,471 Medicare services across 3,688 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kovoor received a total of $11,639 from 51 pharmaceutical and/or device companies across 242 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kovoor is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice▲ Top 5% volume in TX$ $11,639 industry payments
Medicare Practice Summary
Medicare Utilization ↗108,471
Medicare services
Top 5% in TX for hematology & oncology
3,688
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~8,344 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 34,680 | $0 | $5 |
| Oxaliplatin chemotherapy injection | 12,140 | $0 | $33 |
| Pembrolizumab injection (Keytruda) | 11,300 | $43 | $136 |
| Iron sucrose injection (Venofer) | 11,000 | $0 | $2 |
| Contrast dye for imaging (iodine-based) | 9,891 | $0 | $3 |
| Paclitaxel chemotherapy injection | 5,256 | $0 | $8 |
| Injection, bortezomib, 0.1 mg | 3,185 | $3 | $116 |
| Dexamethasone injection (steroid) | 2,966 | $0 | $1 |
| Darbepoetin injection (Aranesp) for anemia | 2,915 | $2 | $20 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 2,282 | $24 | $155 |
| Injection, granisetron hydrochloride, 100 mcg | 1,100 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 890 | $1 | $114 |
| Office visit, established patient (30-39 min) | 762 | $91 | $368 |
| Blood draw (venipuncture) | 732 | $8 | $20 |
| Complete blood count (CBC) with differential | 696 | $8 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 566 | $22 | $157 |
| Injection, fulvestrant, 25 mg | 500 | $8 | $244 |
| Comprehensive metabolic blood panel | 424 | $10 | $64 |
| Administration of chemotherapy into vein, 1 hour or less | 411 | $98 | $707 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 396 | $80 | $1,348 |
| Injection, leucovorin calcium, per 50 mg | 388 | $3 | $25 |
| Injection, fluorouracil, 500 mg | 374 | $2 | $13 |
| Iron level test | 313 | $6 | $27 |
| Iron binding capacity test | 313 | $9 | $35 |
| Ferritin level test (iron stores) | 312 | $13 | $60 |
| Cyclophosphamide, 100 mg | 272 | $15 | $203 |
| Injection of additional new drug or substance into vein | 269 | $12 | $108 |
| Injection, zoledronic acid, 1 mg | 232 | $7 | $431 |
| Lactate dehydrogenase (enzyme) level | 228 | $6 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 214 | $47 | $313 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 203 | $51 | $211 |
| Injection, carboplatin, 50 mg | 199 | $2 | $300 |
| Injection, potassium chloride, per 2 meq | 185 | $0 | $1 |
| Administration of chemotherapy into vein, each additional hour | 182 | $21 | $161 |
| Injection, magnesium sulfate, per 500 mg | 180 | $1 | $6 |
| Administration of additional new drug or substance into vein, 1 hour or less | 169 | $48 | $344 |
| Hospital follow-up visit, high complexity | 167 | $90 | $357 |
| Infusion, normal saline solution , 1000 cc | 155 | $2 | $19 |
| Injection, diphenhydramine hcl, up to 50 mg | 137 | $1 | $7 |
| Drug injection, under skin or into muscle | 120 | $10 | $96 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 102 | $348 | $1,722 |
| Ct scan of chest with contrast | 94 | $35 | $821 |
| Unclassified drugs | 90 | $1 | $8 |
| Infusion into a vein for hydration, 31-60 minutes | 89 | $24 | $256 |
| CT scan of abdomen and pelvis with contrast | 86 | $132 | $1,067 |
| Microscopic examination for white blood cells with manual cell count | 73 | $4 | $22 |
| Complete blood count (CBC), automated | 73 | $6 | $34 |
| Reticulated (young) platelet measurement | 70 | $35 | $143 |
| Administration of additional new drug or substance into vein using push technique | 69 | $41 | $289 |
| Carcinoembryonic antigen (cea) protein level | 68 | $19 | $99 |
| Irrigation of implanted venous access drug delivery device | 60 | $18 | $114 |
| Red blood count automated, with additional calculations | 57 | $5 | $26 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 55 | $25 | $145 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 50 | $124 | $500 |
| New patient office visit (45-59 min) | 49 | $121 | $565 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 49 | $91 | $657 |
| Infusion into a vein for hydration, each additional hour | 46 | $9 | $75 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 46 | $16 | $100 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 44 | $15 | $94 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 43 | $272 | $2,762 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 43 | $1 | $19 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 40 | $1,109 | $4,802 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 40 | $141 | $3,675 |
| Administration of chemotherapy into vein using push technique | 36 | $74 | $500 |
| Application of on-body injector for under skin injection | 32 | $14 | $96 |
| CT scan of chest, without contrast | 31 | $41 | $686 |
| Drawing of blood for a medical problem | 30 | $66 | $264 |
| Basic metabolic blood panel | 28 | $7 | $49 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $1 | $17 |
| Office visit, established patient, complex (40-54 min) | 24 | $128 | $496 |
| Office visit, established patient (20-29 min) | 23 | $60 | $250 |
| Ct scan of soft tissue of neck with contrast | 18 | $50 | $658 |
| Ct scan of abdomen and pelvis without contrast | 16 | $64 | $560 |
| Calcium level, total | 15 | $5 | $30 |
| New patient office visit, complex (60-74 min) | 15 | $167 | $709 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 15 | $178 | $700 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | 12 | $177 | $700 |
| Initial hospital admission, high complexity | 11 | $133 | $694 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
33.1% high complexity
62.0% medium
4.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,639
Total received (2018-2024)
Avg $1,663/year across 7 years
Top 29% in TX for hematology & oncology
51
Companies
242
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,710 (49.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,480 (21.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,093 (18.0%)
Other
Charitable contributions, space rental, and other categories
$1,357 (11.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,258
2023$651
2022$3,405
2021$1,338
2020$171
2019$1,005
2018$1,811
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Rigel Pharmaceuticals, Inc.
$1,558
Novartis Pharmaceuticals Corporation
$1,528
Janssen Scientific Affairs, LLC
$1,101
AstraZeneca Pharmaceuticals LP
$912
E.R. Squibb & Sons, L.L.C.
$600
Pharmacyclics LLC, An AbbVie Company
$526
BeiGene, Ltd.
$525
Janssen Biotech, Inc.
$501
Amgen Inc.
$420
Seattle Genetics, Inc.
$387
PFIZER INC.
$358
Incyte Corporation
$320
Merck Sharp & Dohme LLC
$310
Gilead Sciences, Inc.
$253
Seagen Inc.
$229
Regeneron Healthcare Solutions, Inc.
$196
GlaxoSmithKline, LLC.
$196
Celgene Corporation
$163
Astellas Pharma US Inc
$161
Karyopharm Therapeutics Inc.
$158
Ipsen Biopharmaceuticals, Inc
$125
Dendreon Pharmaceuticals LLC
$122
Epizyme, Inc.,
$100
SANOFI-AVENTIS U.S. LLC
$99
ABBVIE INC.
$96
GENZYME CORPORATION
$87
ARRAY BIOPHARMA INC
$41
Kite Pharma, Inc.
$38
Pharmacyclics LLC, an AbbVie Company
$37
Mirati Therapeutics, Inc.
$37
Merck Sharp & Dohme Corporation
$36
ADC Therapeutics America, Inc.
$33
Alexion Pharmaceuticals, Inc.
$33
PUMA BIOTECHNOLOGY, INC.
$32
EMD Serono, Inc.
$31
Lilly USA, LLC
$29
Exelixis Inc.
$23
Eisai Inc.
$21
Acrotech Biopharma Inc.
$20
EISAI INC.
$20
Deciphera Pharmaceuticals Inc.
$19
MorphoSys, US Inc.
$19
TESARO, Inc.
$18
Takeda Pharmaceuticals U.S.A., Inc.
$18
MENARINI SILICON BIOSYSTEMS, INC.
$18
Helsinn Therapeutics (U.S.), Inc.
$17
Puma Biotechnology, Inc.
$17
Secura Bio, Inc.
$15
Dova Pharmaceuticals
$15
Blueprint Medicines Corporation
$14
Sirtex Medical Inc
$6
Top 3 companies account for 36.0% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALOXI · AYVAKIT · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CALQUENCE · CARVYKTI · COPIKTRA · CRESEMBA · CYRAMZA · Cabometyx · Cellsearch · DARZALEX · Doptelet · ELIQUIS · ENHERTU · ENJAYMO · EPKINLY · Fabhalta · GAUCHER-DISEASE · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NERLYNX · Neulasta · Nplate · OJJAARA · ONIVYDE · ONUREG · OPDIVO · OPDUALAG · PADCEV · PLUVICTO · PROVENGE · Prolia · QINLOCK · REBLOZYL · Revlimid · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SUTENT · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · Tavalisse · Trodelvy · ULTOMIRIS · VENCLEXTA · VONVENDI · VOTRIENT · WELIREG · XALKORI · XPOVIO · XTANDI · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (49%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $11 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
129
Per 100K population
11.6
County median income
$117,588
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL PLANO
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kovoor is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), and mixed engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kovoor experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Kovoor performed 34,680 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kovoor receive payments from pharmaceutical companies?
Yes. Dr. Kovoor received a total of $11,639 from 51 companies across 242 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kovoor's costs compare to other hematology & oncologys in Plano?
Dr. Kovoor's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kovoor) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Plano
Browse hematology & oncologys in Plano ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Rigel Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Rigel Pharmaceuticals, Inc..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Scientific Affairs, LLC Payments to Doctors
See all physicians who received payments from Janssen Scientific Affairs, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology